Get the Stockscreener App
0.5008
3.38%
-0.0175
After Hours:
.51
0.0092
+1.84%
Century Therapeutics Inc stock is traded at $0.5008, with a volume of 309.74K.
It is down -3.38% in the last 24 hours and down -3.32% over the past month.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
See More
Previous Close:
$0.5183
Open:
$0.503
24h Volume:
309.74K
Relative Volume:
0.37
Market Cap:
$43.26M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.2187
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
-0.77%
1M Performance:
-3.32%
6M Performance:
-16.62%
1Y Performance:
-67.48%
1-Day Range:
$0.492
$0.5129
1-Week Range:
$0.492
$0.5193
52-Week Range:
$0.3418
$1.8599
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.5008 | 43.86M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Ranking Century Therapeutics Inc. among high performing stocks via toolsAnalyst Upgrade & Short-Term High Return Strategies - Newser
Using RSI to spot recovery in Century Therapeutics Inc.July 2025 Reactions & Low Risk Entry Point Guides - Newser
Published on: 2025-09-12 19:08:54 - Newser
Can Century Therapeutics Inc. hit a new high this month2025 Market Trends & Fast Entry Momentum Trade Alerts - Newser
What moving averages say about Century Therapeutics Inc.2025 Short Interest & Daily Risk Controlled Trade Plans - Newser
Will Century Therapeutics Inc. stock go up soonTrade Entry Summary & High Yield Equity Trading Tips - Newser
Multi factor analysis applied to Century Therapeutics Inc.Weekly Stock Report & Free High Return Stock Watch Alerts - Newser
Real time social sentiment graph for Century Therapeutics Inc.Earnings Trend Report & Long Hold Capital Preservation Plans - Newser
Trend analysis for Century Therapeutics Inc. this weekMarket Volume Summary & Smart Investment Allocation Insights - Newser
How to use Fibonacci retracement on Century Therapeutics Inc.Market Growth Report & Fast Momentum Entry Tips - Newser
Real time breakdown of Century Therapeutics Inc. stock performance2025 Macro Impact & Capital Protection Trading Alerts - Newser
What MACD signals say about Century Therapeutics Inc.Earnings Risk Summary & High Accuracy Buy Signal Tips - Newser
Statistical indicators supporting Century Therapeutics Inc.’s strengthMarket Growth Summary & Real-Time Volume Analysis - Newser
What earnings revisions data tells us about Century Therapeutics Inc.Market Performance Recap & Fast Exit and Entry Strategy Plans - Newser
Price action breakdown for Century Therapeutics Inc.July 2025 Highlights & Real-Time Volume Analysis - Newser
How to track smart money flows in Century Therapeutics Inc.Market Activity Report & Technical Confirmation Trade Alerts - Newser
Quantitative breakdown of Century Therapeutics Inc. recent moveQuarterly Market Review & AI Enhanced Execution Alerts - Newser
Published on: 2025-09-11 00:04:25 - Newser
Detecting price anomalies in Century Therapeutics Inc. with AIQuarterly Portfolio Summary & Proven Capital Preservation Tips - Newser
Century therapeutics (IPSC) CEO Pfeiffenberger sells $244 in stock - Investing.com
Russotti, Century Therapeutics officer, sells $269 in stock - Investing.com
Reversal indicators forming on Century Therapeutics Inc. stockMarket Growth Report & Stepwise Trade Signal Implementation - Newser
Update Report: Is Century Therapeutics Inc. stock undervalued right nowFed Meeting & AI Based Buy and Sell Signals - Lancaster City Council
Should I add Century Therapeutics Inc. stock to my portfolioMarket Sentiment Review & Low Risk High Win Rate Picks - Lancaster City Council
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):